

Charity Registration No. 285946

Company Registration No. 493724 (England and Wales)

**THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**  
**ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## LEGAL AND ADMINISTRATIVE INFORMATION

---

<b>Trustees</b>	Dr Zaloa Agirre-Arrizubieta	
	Professor Mark Baker Dr	
	Natalie Ross Dr Charles Fry	
	Dr Sushma Goyal Dr Brython	(Appointed 4 October 2024)
	Hywel Dr Samantha	
	Jefferson Dr Andrew Michell	
	Dr Friederike Moeller Dr	
	Giulia Navarro Dr Gareth	
	Payne Dr Ronit Pressler Dr	
	Syed Shah Dr Rachel	(Appointed 4 October 2024)
	Thornton Dr Simon Freilich	
	Dr Jiten Mistry Dr Tatyana	
	Yermakova Dr Stephan	(Appointed 4 October 2024)
	Jaiser Professor Martin	
	Koltzenburg	(Resigned 4 October 2024)
		(Resigned 4 October 2024)
<b>Charity number</b>	285946	
<b>Company number</b>	493724	
<b>Registered office</b>	9 Bonhill Street London EC2A 4DJ	
<b>Independent examiner</b>	Katherine Dee FCA ACA Begbies Chartered Accountants 9 Bonhill Street London  EC2A 4DJ	

---

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## CONTENTS

---

	Page
President's statement	1
Trustees' report	2 - 4
Independent examiner's report	5
Statement of financial activities	6 - 7
Summary income and expenditure account	8
Balance sheet	9
Notes to the financial statements	10 - 19

---

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## PRESIDENT'S STATEMENT

***FOR THE YEAR ENDED 30 JUNE 2025***

---

The BSCN has been active this year promoting the specialty and scientific knowledge through two Scientific meetings, including a joint meeting held with the Irish Society of Clinical Neurophysiology at the Radisson Blu St Helen's Hotel, Stillorgan, Dublin, and three training days for the Specialist Trainees across the UK. The Society also continues to promote and support UK Clinical Neurophysiology in other areas; for example, we continue to award an essay prize for medical students to encourage interest in, and consideration of the specialty, and this year we have received a record number of applicants.

The Society's members have also been meeting with NHS England (the Department of Health) and NHS Wales to discuss issues relating to the profession and to lobby for funding for more training posts in our specialty to meet the needs of patients across the UK. The Society continues to award bursaries to UK trainees to help cover training course fees and associated travel costs, and in the 2024-2025 financial year the society has been particularly generous.

Finally, I look forward to interacting with those of our international colleagues (some of whom are also members of the BSCN) attending the European Congress of Clinical Neurophysiology, which will be hosted this year in London.



.....  
**Dr Gareth Payne**  
**President**

5th October 2025  
Date: .....

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

### FOR THE YEAR ENDED 30 JUNE 2025

---

The trustees of The British Society for Clinical Neurophysiology (BSCN) present their report and accounts for the year ended 30 June 2025 and confirm that they comply with current statutory requirements and with the requirements of the Society's governing instrument.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charitable company's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".

#### **Objectives and activities**

The charitable company's objects are to promote and assist the science and practice of electroencephalography, clinical neurophysiology and allied subjects.

The policies adopted in furtherance of these objects are as following and there has been no change in these during the year:

1. To organise scientific meetings of the Society (usually 2-3 per year)
2. To organise teaching courses (triennial)
3. To organise essay prizes in the subject
4. To provide an Annual Medical Student Bursary, of up to £5,000, in support of a Neurosciences BSc.

The trustees consider that they have complied with the duty of section 17(5) of the Charities Act 2011, having paid due regard to public benefit guidance issued by the Charity Commission in deciding what activities the charitable company should undertake.

#### **Achievements and performance**

The BSCN has been involved in presenting the usual two Scientific meetings in Autumn and Spring, with the Spring meeting being held jointly with the Irish Society of Clinical Neurophysiology. Three training days are also held for the Specialist Trainees across the UK.

The BSCN continues to honour achievement in clinical neurophysiology, and award prizes and grants. The total cost of awards for the 2024/5 year was £1,500.

The Medical Student Essay Prize of £500 which was awarded to Thanusa Thatparan of the University of Sheffield.

The Adrian Prize of £1,000 was awarded to Dr Charles Fry.

Book bursaries totalling £159 were awarded to one recipient.

General bursaries totalling £3,188 were awarded to eight people of which £2,688 were ISCN 2025 bursaries.

#### Subscriptions

Income from membership subscriptions increased by 16.9% during the year to 30th June 2025, however as income is recognised on receipt, the difference is largely due to payment timings at the year end.

#### Meetings

Expenses relating to Society meetings amounted to £10,656, and income amounted to £47,135. The cost of events decreased significantly due to the joint Spring scientific meeting.

These costs are directly attributable to the meetings, and are before the share of governance or support costs.

#### Professional fees

Independent Examination for the year were £3,133.

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 30 JUNE 2025

---

### Investments

The market value of the Society's investments increased during the year by £2,075 (2.3%). These investments produced dividends and gross interest of £4,863.

### **Financial review**

The Society's financial position remains very sound. This year the Society reports a net surplus for the year of £45,383; however, the Society always aims to leave sufficient funds in order to fund the running of large events, including future triennial teaching courses in Oxford. After the success of the Society's bid to host the ECCN in 2025, we have been working on the ECCN 2025 budget with a professional conference organiser (PCO), who have set up a limited company, with Dr Nick Kane and Dr Jacquie Deeb as Directors. This will ensure that the Society does not have any financial liability for ECCN 2025 and will not be expected to underwrite the congress. However, given the ECCN will take place instead of the triennial course in 2025, the Society will provide support for the ECCN, as it has previously for the triennial course. The ECCN company is not considered to be a related party to the Society and their activities are not incorporated into these accounts.

### Reserves policy

The Society holds reserves sufficient to underwrite any potential losses in respect of the next triennial teaching course. At the year end the reserves stood at £62,672, of which £10,000 is held as an expendable endowment for the Dr last Memorial fund and £23,086 are restricted funds. The remaining £229,586 unrestricted funds are freely available to support the charitable objects.

### Investments policy

The Society's investments are held in charity-specific low risk unit trusts and fixed interest securities.

### Risk Mitigation

The trustees have reviewed the Society's exposure to major risks and have accordingly established that the Society's reserves are sufficient to mitigate them.

### **Structure, governance and management**

The charitable company is a company limited by guarantee, and is incorporated in England. The company's registered address is 9 Bonhill Street, London, EC2A 4DJ.

The governing instrument is the Memorandum and Articles of Association (updated October 2021). The society is governed by a council of management, which consists of the Officers of the Society, the Chairmen of the Medical and Clinical Scientists Standing Committees, not more than eight ordinary members of the Council (being corporate members of the Society), and such corporate members of the Society (not exceeding three) as may be co-opted by Council at its discretion.

Trustees (Officers of the Society) are appointed in accordance with the Memorandum and Articles of Association. Persons are nominated for election as officers of the Society at least 6 weeks prior to the Annual General Meeting. If more than one person is nominated, a vote is taken at the AGM, otherwise the election is agreed by the council.

Newly appointed Officers are either already experienced in the role, or share duties and shadow the outgoing Officer.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Dr Zaloe Agirre-Arrizubieta

Professor Mark Baker

Dr Natalie Ross

Dr Charles Fry

(Appointed 4 October 2024)

Dr Sushma Goyal

Dr Brython Hywel

Dr Stephan Jaiser

(Resigned 4 October 2024)

Dr Samantha Jefferson

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)

**FOR THE YEAR ENDED 30 JUNE 2025**

---

Professor Martin Koltzenburg	(Resigned 4 October 2024)
Dr Andrew Michell	
Dr Friederike Moeller	
Dr Giulia Navarro	(Appointed 4 October 2024)
Dr Gareth Payne	
Dr Ronit Pressler	
Dr Syed Shah	
Dr Rachel Thornton	
Dr Simon Freilich	
Dr Jiten Mistry	
Dr Tatyana Yermakova	(Appointed 4 October 2024)

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £2 in the event of a winding up.

The trustees' report was approved by the Board of Trustees.



.....  
**Dr Gareth Payne**

Trustee

Dated: 5th October 2025

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## INDEPENDENT EXAMINER'S REPORT

### TO THE TRUSTEES OF THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

---

I report to the trustees on my examination of the financial statements of The British Society for Clinical Neurophysiology (the charitable company) for the year ended 30 June 2025.

#### **Responsibilities and basis of report**

As the trustees of the charitable company (and also its directors for the purposes of company law), you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006.

Having satisfied myself that the financial statements of the charitable company are not required to be audited under Part 16 of the Companies Act 2006 and are eligible for independent examination, I report in respect of my examination of the charitable company's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

#### **Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charitable company as required by section 386 of the Companies Act 2006.
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the Companies Act 2006 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



**Katherine Dee FCA**

Begbies Chartered Accountants  
9 Bonhill Street  
London  
EC2A 4DJ

Dated: ....6/10/25.....



# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 30 JUNE 2025

### Current financial year

		Unrestricted funds 2025	Restricted funds 2025	Endowment funds 2025	Total 2025	Total 2024
	Notes	£	£	£	£	£
<u>Income from:</u>						
Donations and legacies	2	25,905	-	-	25,905	22,162
Charitable activities	3	47,135	-	-	47,135	37,203
Investments	4	5,441	1,309	-	6,750	6,411
<b>Total income</b>		<u>78,481</u>	<u>1,309</u>	<u>-</u>	<u>79,790</u>	<u>65,776</u>
<u>Expenditure on:</u>						
Charitable activities	5	<u>36,482</u>	<u>-</u>	<u>-</u>	<u>36,482</u>	<u>67,686</u>
Net gains/(losses) on investments	11	<u>1,196</u>	<u>-</u>	<u>879</u>	<u>2,075</u>	<u>5,200</u>
<b>Net incoming resources before transfers</b>		<u>43,195</u>	<u>1,309</u>	<u>879</u>	<u>45,383</u>	<u>3,290</u>
Gross transfers between funds		<u>879</u>	<u>-</u>	<u>(879)</u>	<u>-</u>	<u>-</u>
<b>Net movement in funds</b>		<u>44,074</u>	<u>1,309</u>	<u>-</u>	<u>45,383</u>	<u>3,290</u>
Fund balances at 1 July 2024		<u>185,512</u>	<u>21,777</u>	<u>10,000</u>	<u>217,289</u>	<u>213,999</u>
<b>Fund balances at 30 June 2025</b>		<u><u>229,586</u></u>	<u><u>23,086</u></u>	<u><u>10,000</u></u>	<u><u>262,672</u></u>	<u><u>217,289</u></u>

The statement of financial activities includes all gains and losses recognised in the year.

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

### Prior financial year

		Unrestricted funds 2024 £	Restricted funds 2024 £	Endowment funds 2024 £	Total 2024 £
	Notes				
<u>Income from:</u>					
Donations and legacies	2	22,162	-	-	22,162
Charitable activities	3	37,203	-	-	37,203
Investments	4	5,167	1,244	-	6,411
<b>Total income</b>		64,532	1,244	-	65,776
<u>Expenditure on:</u>					
Charitable activities	5	67,199	487	-	67,686
Net gains/(losses) on investments	11	3,596	-	1,604	5,200
<b>Net incoming resources before transfers</b>		929	757	1,604	3,290
Gross transfers between funds		1,604	-	(1,604)	-
<b>Net movement in funds</b>		2,533	757	-	3,290
Fund balances at 1 July 2023		182,979	21,020	10,000	213,999
<b>Fund balances at 30 June 2024</b>		185,512	21,777	10,000	217,289

The statement of financial activities includes all gains and losses recognised in the year.

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## SUMMARY INCOME AND EXPENDITURE ACCOUNT

*FOR THE YEAR ENDED 30 JUNE 2025*

---

	<b>All income funds 2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Gross income	79,790	65,776
Gains on investments	1,196	3,596
Transfer from endowment funds	879	1,604
	<hr/>	<hr/>
Total income in the reporting period	81,865	70,976
	<hr/>	<hr/>
Total expenditure from income funds	36,482	67,686
	<hr/>	<hr/>
<b>Net income for the year</b>	<b>45,383</b>	<b>3,290</b>
	<hr/> <hr/>	<hr/> <hr/>

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## BALANCE SHEET

AS AT 30 JUNE 2025

	Notes	2025 £	£	2024 £	£
<b>Fixed assets</b>					
Investments	13		90,964		88,889
<b>Current assets</b>					
Debtors	14	5,382		916	
Cash at bank and in hand		169,605		138,903	
		174,987		139,819	
<b>Creditors: amounts falling due within one year</b>	15	(3,279)		(11,419)	
<b>Net current assets</b>			171,708		128,400
<b>Net assets</b>			262,672		217,289
<b>The funds of the charitable company</b>					
Endowment funds	17	10,000		10,000	
Restricted income funds	18	23,086		21,777	
Unrestricted funds		229,586		185,512	
		262,672		217,289	

For the year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 10th September 2025



Professor Mark Baker  
Trustee



Dr Gareth Payne  
Trustee

Company registration number 493724 (England and Wales)

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS

**FOR THE YEAR ENDED 30 JUNE 2025**

---

### 1 Accounting policies

#### Charity information

The British Society for Clinical Neurophysiology is a private company limited by guarantee incorporated in England and Wales. The registered office is 9 Bonhill Street, London, EC2A 4DJ.

All of the trustees are members of the company and guarantee to contribute £2 in the event of a winding up.

#### 1.1 Accounting convention

The financial statements have been prepared in accordance with the charitable company's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charitable company is a Public Benefit Entity as defined by FRS 102.

The charitable company has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charitable company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

#### 1.3 Charitable funds

##### MSC Fund

The Medical Standing Committee fund was established from the residual reserves of the Association of British Clinical Neurophysiologists, which were donated during the year ended 30 June 2006. No travel expenses were reimbursed from this fund during the year.

##### The Christine and Adrian Fowle Prize Fund

This prize fund, established by past president of the society Adrian Fowle and his wife Christine is intended to recognise excellence in the practice of clinical neurophysiology other than in science, and in particular in its human aspects. £5,000 (plus £1,250 of gift aid) was donated to the Society in 2020.

##### Dr Last Memorial Fund

This expendable endowment fund was established by a generous donation from Dr Last's family and a contribution from the Society's reserves. Its purpose is to further the objectives of the Society, in particular in assisting younger members, by making grants to support foreign travel, enabling the recipient to visit laboratories where they may wish to learn new techniques or to plan or carry out joint research. It was not originally intended that funds should be used to facilitate attendance at conferences but it has been subsequently agreed that the fund may be used to finance bursaries. The fund originally comprised £10,000 of M & G Charifund units which yield an annual income and provides capital growth. During the year the investment generated investment income of £1,244. The committee will intend to distribute the annual income from the fund and may sell units to give additional finance provided that the market value of the capital invested in the fund does not fall below £10,000. It may make awards to one or more applicants or make no award if applicants are not considered suitable or if insufficient funds are available.

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 30 JUNE 2025

---

#### 1 Accounting policies

(Continued)

##### 1.4 Incoming resources

Incoming resources from charitable activities are recognised on an accruals basis. Investment income is received gross and accounted for on an accruals basis.

Cash donations are recognised on receipt. Membership fees are recorded as donations.

No provision has been made in these accounts for subscriptions unpaid at the end of the year. Subscriptions are recognised in full in the year in which they are received.

##### 1.5 Resources expended

Resources expended are recognised in the year in which they are incurred. Support costs are those costs incurred in support of expenditure on the objects of the charity. Governance costs are those incurred in connection with compliance with constitutional and statutory requirements. No support or governance cost are allocated to the category of awards and prizes as the general overhead time is immaterial.

##### 1.6 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

##### 1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

##### 1.8 Financial instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charitable company's balance sheet when the charitable company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

### 1 Accounting policies

(Continued)

#### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

#### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the charitable company's contractual obligations expire or are discharged or cancelled.

### 2 Donations and legacies

	2025 £	2024 £
Membership fees	25,905	22,162
	<u>25,905</u>	<u>22,162</u>

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

**FOR THE YEAR ENDED 30 JUNE 2025**

### 3 Charitable activities

	2025 £	2024 £
Delegate fee income	37,335	17,003
Exhibitor fee income	9,800	20,200
	<u>47,135</u>	<u>37,203</u>
<i>Analysis by fund</i>		
Unrestricted funds	<u>47,135</u>	
<b>For the year ended 30 June 2024</b>		
Unrestricted funds		<u>37,203</u>
		<u>37,203</u>

Income from charitable activities consists of income from three scientific meetings (2024: three), and two courses (2024: two).

### 4 Investments

	Unrestricted funds £	Restricted funds £	Total 2025 £	Total 2024 £
Income From Listed Investments	3,191	1,309	4,500	4,167
Bank Interest	2,250	-	2,250	2,244
	<u>5,441</u>	<u>1,309</u>	<u>6,750</u>	<u>6,411</u>
<b>For the year ended 30 June 2024</b>	<u>5,167</u>	<u>1,244</u>		<u>6,411</u>



# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

### 5 Charitable activities

	Scientific Meetings	Grants and Awards	Total 2025	Total 2024
	£	£	£	£
Meeting costs	10,656	-	10,656	22,273
Grant funding of activities (see note 6)	-	4,847	4,847	15,819
Share of support costs (see note 7)	17,811	-	17,811	24,198
Share of governance costs (see note 7)	3,168	-	3,168	5,396
	<u>31,635</u>	<u>4,847</u>	<u>36,482</u>	<u>67,686</u>
<u>Analysis by fund</u>				
Unrestricted funds	<u>31,635</u>	<u>4,847</u>	<u>36,482</u>	
	<u>31,635</u>	<u>4,847</u>	<u>36,482</u>	
<b>For the year ended 30 June 2024</b>				
Meeting costs	22,273	-		22,273
Grant funding of activities (see note 6)	-	15,819		15,819
Share of support costs (see note 7)	24,198	-		24,198
Share of governance costs (see note 7)	5,396	-		5,396
	<u>51,867</u>	<u>15,819</u>		<u>67,686</u>
<u>Analysis by fund</u>				
Unrestricted funds	<u>51,380</u>	<u>15,819</u>		<u>67,199</u>
Restricted funds	<u>487</u>	<u>-</u>		<u>487</u>
	<u>51,867</u>	<u>15,819</u>		<u>67,686</u>

### 6 Grants payable

	2025 £	2024 £
Grants to individuals	<u>4,847</u>	<u>15,819</u>
	<u>4,847</u>	<u>15,819</u>
<b>For the year ended 30 June 2024</b>	<u>13,860</u>	
Grants and Awards		

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

### 6 Grants payable

(Continued)

2025

General grants paid by the charitable company, consisting of the Adrian Prize for £1,000, the Medical Student Essay Prize for £500, and 7 bursaries totalling £2,688 to reimburse trainees attending the joint BSCN & ISCN Spring Meeting in Dublin and one bursary for £500 to attend an ISIN training course. In addition one book bursary was awarded.

2024

General grants paid by the charitable company, consisting of the Adrian Prize for £1,000, the Medical Student Essay Prize for £500, and 11 bursaries of £500 each (totalling £5,500) to reimburse trainees attending the EEG Course in Cambridge. In addition 8 book bursaries were awarded.

### 7 Support costs

	Support costs	Governance costs	2025	2024
	£	£	£	£
Website	1,289	-	1,289	6,660
Clerical Assistance	14,107	-	14,107	15,451
Subscription - IFCN	1,100	-	1,100	1,149
Subscription - JNC	250	-	250	250
Subscription - AANEM	204	-	204	-
Bank charges	789	-	789	262
Sundry expenses	72	-	72	426
Examination fees	-	3,133	3,133	2,893
Legal and professional	-	35	35	2,265
Trustee meeting and dinner	-	-	-	238
	<u>17,811</u>	<u>3,168</u>	<u>20,979</u>	<u>29,594</u>
Analysed between				
Charitable activities	<u>17,811</u>	<u>3,168</u>	<u>20,979</u>	<u>29,594</u>

2025

All support costs are attributable to scientific meetings.

2024

All support costs are attributable to scientific meetings.

Governance costs includes accountants' fees of £3,113 (2024- £2,893) for examination fees.

### 8 Net movement in funds

2025  
£

2024  
£

The net movement in funds is stated after charging/(crediting):

Fees payable for the independent examination of the charity's financial statements	<u>3,133</u>	<u>2,893</u>
--	--------------	--------------

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 30 JUNE 2025

#### 9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charitable company during the year (2024: £0). No trustees claimed travel expenses (2024: 3 trustees: £913)

#### 10 Employees

The charitable company had no employees during the current or prior year.

There were no employees whose annual remuneration was more than £60,000.

#### 11 Gains and losses on investments

	Unrestricted Endowment		Total Unrestricted Endowment			Total
	funds	funds		funds	funds	
	2025	2025	2025	2024	2024	2024
Gains/(losses) arising on:	£	£	£	£	£	£
Revaluation of investments	1,196	879	2,075	3,596	1,604	5,200
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>

#### 12 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

#### 13 Fixed asset investments

	Listed investments	Unlisted investments	Total
	£	£	£
<b>Valuation</b>			
At 1 July 2024	78,889	10,000	88,889
Additions	80,562	-	80,562
Valuation changes	2,075	-	2,075
Disposals	(80,562)	-	(80,562)
	<u>          </u>	<u>          </u>	<u>          </u>
At 30 June 2025	80,964	10,000	90,964
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Carrying amount</b>			
At 30 June 2025	80,964	10,000	90,964
	<u>          </u>	<u>          </u>	<u>          </u>
At 30 June 2024	78,889	10,000	88,889
	<u>          </u>	<u>          </u>	<u>          </u>

The original cost of the above investments totalled £90,562 (2024: £75,000). At the balance sheet date the listed investments held were M&G Charity Multi Asset Fund which is a unit trust. The unlisted investment is an NS&I Income Bond savings account.

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

### 14 Debtors

	2025 £	2024 £
<b>Amounts falling due within one year:</b>		
Other debtors	3,419	-
Prepayments and accrued income	1,963	916
	<u>5,382</u>	<u>916</u>

### 15 Creditors: amounts falling due within one year

	Notes	2025 £	2024 £
Deferred income	16	-	8,140
Accruals		3,279	3,279
		<u>3,279</u>	<u>11,419</u>

### 16 Deferred income

	2025 £	2024 £
Deferred scientific meeting delegate and exhibitor fees	-	8,140
	<u>-</u>	<u>8,140</u>

Deferred income consists of delegate and exhibitor fees received in advance of next year's scientific meetings.

### 17 Endowment funds

Endowment funds represent assets which must be held permanently by the charitable company. Income arising on the endowment funds can be used in accordance with the objects of the charitable company and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.

	At 1 July 2024 £	Transfers £	Gains and losses £	At 30 June 2025 £
<b>Expendable endowments</b>	<u>10,000</u>	<u>(879)</u>	<u>879</u>	<u>10,000</u>

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 30 JUNE 2025

#### 17 Endowment funds

(Continued)

Previous year:	At 1 July 2023	Transfers	Gains and losses	At 30 June 2024
	£	£	£	£
<b>Expendable endowments</b>				
	10,000	(1,604)	1,604	10,000

#### 18 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 July 2024	Incoming resources	Resources expended	At 30 June 2025
	£	£	£	£
MSC Fund	12,006	-	-	12,006
Dr Last Memorial Fund	4,521	1,309	-	5,830
Christine and Adrian Fowle Prize Fund	5,250	-	-	5,250
	21,777	1,309	-	23,086

Previous year:	At 1 July 2023	Incoming resources	Resources expended	At 30 June 2024
	£	£	£	£
MSC Fund	12,006	-	-	12,006
Dr Last Memorial Fund	3,277	1,244	-	4,521
Christine and Adrian Fowle Prize Fund	5,250	-	-	5,250
Visit Britain ECCN grant	487	-	(487)	-
	21,020	1,244	(487)	21,777

#### 19 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 July 2024	Incoming resources	Resources expended	Transfers	Gains and losses	At 30 June 2025
	£	£	£	£	£	£
General funds	185,512	78,481	(36,482)	879	1,196	229,586

# THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

### 19 Unrestricted funds

(Continued)

Previous year: At 1 July 2023	Incoming resources	Resources expended	Transfers	Gains and losses	At 30 June 2024
£	£	£	£	£	£
General funds	182,979	64,532	(67,199)	1,604	3,596
					185,512

### 20 Analysis of net assets between funds

	Unrestricted Fund	Restricted Funds	Endowment Fund	Total
	£	£	£	£
Fund balances at 30 June 2025 are represented by:				
Investments	80,964	-	10,000	90,964
Current assets/(liabilities)	148,622	23,086	-	171,708
	229,586	23,086	10,000	262,672
	£	£	£	£
Fund balances at 30 June 2024 were represented by:				
Investments	78,889	-	10,000	88,889
Current assets/(liabilities)	106,623	21,777	-	128,400
	185,512	21,777	10,000	217,289

### 21 Related party transactions

There were no disclosable related party transactions during the year (2024 - none), aside from the award of the £1,000 Adrian Prize to trustee Dr Charles Fry.